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sensitization by decreasing the dopamine level in
rat nucleus accumbens
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Background: Repeated morphine exposure can induce behavioral sensitization. There are evidences have shown
that central gamma-aminobutyric acid (GABA) system is involved in morphine dependence. However, the effect of a
GABAB receptor agonist baclofen on morphine-induced behavioral sensitization in rats is unclear.
Methods: We used morphine-induced behavioral sensitization model in rat to investigate the effects of baclofen on
behavioral sensitization. Moreover, dopamine release in the shell of the nucleus accumbens was evaluated using
microdialysis assay in vivo.
Results: The present study demonstrated that morphine challenge (3 mg/kg, s.c.) obviously enhanced the
locomotor activity following 4-day consecutive morphine administration and 3-day withdrawal period, which
indicated the expression of morphine sensitization. In addition, chronic treatment with baclofen (2.5, 5 mg/kg)
significantly inhibited the development of morphine sensitization. It was also found that morphine challenge 3 days
after repeated morphine administration produced a significant increase of extracellular dopamine release in nucleus
accumbens. Furthermore, chronic treatment with baclofen decreased the dopamine release induced by morphine
challenge.
Conclusions: Our results indicated that gamma-aminobutyric acid system plays an important role in the morphine
sensitization in rat and suggested that behavioral sensitization is a promising model to study the mechanism
underlying drug abuse.
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Repeated morphine administration can induce the neuro-
chemical effects including mainly protein components and
neurotransmission adaptations in the brain, which results
in behavioral response underlying opioid dependence [1].
There are abundant reports have shown that locomotion
sensitization has been suggested to mimic the brain changes
that occur in the human addict [1-3], so it is intriguing* Correspondence: hyhuangs@gmail.com
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reproduction in any medium, provided the oranimal model used to study neural mechanisms related to
opioid dependence [4,5]. Morphine administration can
produce a robust enhancement of locomotor activity in
mice [6,7]. However, it induced dramatically an initial de-
crease and then an increase in locomotor activity in rats
[1,8]. Hence, investigation of sensitization in rats may be
interesting to better understand the potential mechanisms
resulting in opioid dependence.
There are increasing findings have demonstrated that
the mesolimbic dopamine (DA) system especially project-
ing from the ventral tegmental area (VTA) of the midbrain
to the nucleus accumbens(NAc) is definitely involved in
opioid dependence [9-12]. Opioids can increase DAergic
transmission to the NAc by inhibiting the GABAergicThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neurotransmitter systems have been recently found to be
involved in opioid addiction such as glutamatergic system
[15]. Recent evidence has indicated that the GABAergic
system is closely related to the mesolimbic dopaminergic
system and involved in the modulation of addictive behav-
ior [16-19].
Abundant convincing evidences have revealed that
the GABAB receptor agonist can suppress many behavior
changes induced by opioid and non-opioid [17]. It has
been reported that GABAB receptor agonist decreases the
cocaine and nicotine self-administration [20,21], blocks
expression and sensitization of anxiety-like behavior induced
by ethanol withdrawal [22], and suppresses the development
of sensitization to the locomotor of amphetamine [23]. In
addition, GABAergic potentiation following chronic mor-
phine treatment attenuates the rewarding effects of opioids
in the ventral tegmental area [24]. Above reports have indi-
cated that gamma-aminobutyric acid transmission is more
and more concerned.
Our current data focused on baclofen, a potent GABAB
receptor agonist, which was synthesized 30 years before a
GABAB receptor was found and possesses a high affinity
for the GABAB receptors and a strong intrinsic activity
[17,25]. In the present study, we used the rat behavioral
sensitization model to further study the effect of GABAB
receptor agonist on opioid dependence. The current study
investigated the effect of baclofen on the development and
expression of behavioral sensitization induced by mor-
phine. Furthermore the effect of baclofen on extracellular
DA release in NAc was also assessed.Methods
Animals
Male Sprague–Dawley rats (Changchun Animal Center,
China), weighing 250–270 g were used in the present study.
All animals were housed individually in a temperature-
and humidity-controlled room with food and water freely
available under a 12-h light/dark cycle (lights on between
7:00 A.M. and 7:00 P.M.). Rats were acclimated to the
housing conditions and handled daily for 3–4 days before
the experiments began. All experiments were carried out
during the light phase of the cycle. All animal use proce-
dures were approved by the Jilin University Medical Cen-
ter Animal Care and Use Committee and were conducted
in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals.Drugs
Morphine hydrochloride was purchased from Qinghai
Pharmaceutical Factory, China. Baclofen was obtained
from Sigma (St. Louis, MO, USA). All drugs were dis-
solved with saline and injected in a volume of 1.0 ml/kg.Morphine and baclofen were given subcutaneously (s.c.).
Sodium pentobarbital was given intraperitoneally (i.p.).
The induction of morphine sensitization in rat
The apparatus for the measurement of locomotor ac-
tivity consisted of eight chambers (60 × 60 × 40 cm). A
video system was used to track the movement of the
rats in each chamber for 3 h and the distance traveled
was subsequently analyzed by software (Jiliang Software
Company, Shanghai, China). The protocol for locomo-
tion sensitization induced by morphine was based on
previous studies [26]. For all tests, the rats were habi-
tuated to the chamber for 15 min prior to the s. c. in-
jection. The protocol includes 4 days of morphine repeated
treatment, followed by 3 days of withdrawal. Then,
Morphine (3 mg/kg, s.c.) challenge testing was performed
on day 8. Repeated treatment was as follows: On day 1,
rats were habituated to chamber for 15 min, and then
given morphine (10 mg/kg, s.c.). After the morphine in-
jection, the rats were returned immediately to the cham-
ber where locomotor activity was monitored for 3 h. On
days 2, rats were given morphine (10 mg/kg, s.c.) twice
daily. The first injection was given at 7:00 am after a
15-min habituation in the chambers, and then loco-
motor activity was monitored for 3 h, while the second
morphine was given at 5:00 pm in the home cages. On
days 3–4, rats were given morphine (20 mg/kg, s.c.)
twice daily. The first injection and the second morphine
injection had been described above. After the 3-day with-
drawal period without treatment, rats were subjected to an
acute challenge of morphine (3 mg/kg s.c.) to test the ex-
pression of behavioral sensitization on day 8. Two groups
of rats were given morphine and saline (1 ml/kg, s.c.) for
4 consecutive days and their activity was measured for
3 h after each administration as described above.
Effects of the GABAB receptor agonist baclofen on
locomotor activity in rat
In order to study the effect of acute and chronic adminis-
tration of baclofen on locomotor activity, four groups of
rats were exposed to saline or baclofen (1.25, 2.5, 5 mg/kg,
s.c.) for 8 continuous days. On days 1 and 8, the rats were
administered saline or baclofen and then put into the test
chambers to monitor the locomotor activity for 3 h.
Effects of the GABAB receptor agonist baclofen on the
acute morphine stimulation of locomotion in rat
In order to study the effect of baclofen on acute morphine-
induced locomotion, four groups of rats were exposed to
morphine and one group of rats was given saline. For
morphine treatment group, saline or baclofen (1.25, 2.5,
5 mg/kg, s.c.) was administered 15 min prior to the mor-
phine injection. Locomotor activity was measured for 3 h
on day 1 immediately after morphine administration.
Figure 1 Location of the microdialysis probe in the shell
portion of the nucleus accumbens. Schematic representation of
the location of the dialysis probes in the shell portion of the nucleus
accumbens for all rats included in the experiment.
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of morphine-induced sensitization
Four groups of rats were exposed to morphine and one
group of rats was given saline for 4 consecutive days as
described above. After a 3-day withdrawal period, all five
groups of animals were subjected to an acute challenge
of morphine (3 mg/kg, s.c.) on day 8. Four morphine-
treated groups were pretreated with saline or baclofen
(1.25, 2.5, 5 mg/kg, s.c.) 15 min prior to the morphine
challenge. The locomotor activity was monitored for 3 h
in the chambers.
Effects of chronic treatment of baclofen on the
development of morphine sensitization
Four groups of rats were exposed to morphine and one
group of rats was given saline for 4 consecutive days. For
morphine group, saline or baclofen (1.25, 2.5, 5 mg/kg, s.
c.) was concomitantly administered 15 min prior to the
morphine injection. During a 3-day withdrawal period,
rats in morphine group were still injected with saline or
baclofen (1.25, 2.5, 5 mg/kg, s.c.) daily. On day 8, all five
groups of animals were subjected to an acute challenge
of morphine (3 mg/kg, s.c.). Locomotor activity was mea-
sured for 3 h in the chambers immediately after mor-
phine administration.
In vivo microdialysis experiments
The rats were anaesthetized with sodium pentobarbital
(50 mg/kg, i.p.) and placed in a stereotaxic frame. The
skull was exposed and one small hole was drilled for im-
plantation of the microdialysis probes. Stereotaxic coor-
dinates for the NAc shell were determined according to
the previous report [27]. The coordinates were antero-
posterior (AP) 1.7 mm from the bregma, mediolateral
(ML) ± 0.6 mm, and dorsoventral (DV) −6.0 mm from
the surface of the skull (Figure 1). The microdialysis
probe was perfused with sterilized artificial cerebrospinal
fluid (in mM): NaCl 147, KCl 4, CaCl2 2.2, pH 7.4 [26].
The microdialysis samples were collected by the micro-
syringe pump (ESP-64, Eicom, Japan) at the microdialysis
rate of 1.5 μl/min every 20 min after 1 h of equilibration.
DA and its metabolites in dialysates were measured by
high-performance liquid chromatography (HPLC) using
electrochemical detection with a glassy carbon electrode.
The mobile phase consisted of 85 mM citrate, 100 mM
sodium acetate, 0.9 mM octyl-sodium sulfate, 0.2 mM
EDTA, and 15% methanol, pH 3.7. The mobile phase
was pumped at 600 ul/min with a Lachrom system
(Eicom-Hitachi, Japan) and the separation was performed
with a microbore reverse-phase column (DIKMA Tech-
nologies Ltd., Beijing, China).The volume of injection was
50 μl.
The treatment protocol was as described above. Implant-
ation of the microdialysis probes was performed during the3-day morphine withdrawal period. On day 8, following the
basal levels of DA became stable, all rats were given a chal-
lenge dose of morphine (3 mg/kg, s.c.) and the dialysates
were monitored for 3 h. At the end of each experiment,
rats were sacrificed by overdose injection of pentobarbital
sodium, and their brains were fixed in 10% neutral-buffered
formalin. The location of the dialysis probes was verified
histologically with cresyl violet staining.
Statistical analysis
Data are expressed as mean ± S.E.M. Student’s t-test was
used to compare the difference between two experimental
groups, and one- way analysis of variance (ANOVA) was
used to compare the differences among three or more
groups, followed by Newman-Keuls Multiple Comparison
Test. For induction of morphine sensitization, Data were
analyzed with a repeated two- way ANOVA and Post hoc
tests were conducted using Bonferroni tests; For the micro-
dialysis experiments, the average of the last three samples
was considered to be the baseline and defined as 100%; All
statistical tests were two-tailed and significance was defined
as p< 0.05.
Results
Repeated morphine treatment induced behavioral
sensitization in rat
Two groups of rats were given saline or morphine for 4
consecutive days as described above and their locomotor
Figure 3 Effects of acute and chronic administration of
baclofen on locomotor activity in rat. Rats were exposed to saline
or baclofen (1.25, 2.5, 5 mg/kg, s.c.) for 8 continuous days. On days 1
(a) and 8 (b), the rats were administered saline or baclofen and then
put into the test chambers to monitor the locomotor activity for 3 h.
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daily. As shown in Figure 2, after 4 -day consecutive mor-
phine administration, Repeated one-way ANOVA revealed
that morphine treatment for 4 days significantly enhance
the locomotor activity in rats (F(3, 21) = 3.21, P <0.05).
Newman-Keuls multiple comparison test indicated that
the locomotor activity differed significantly between
day 1 and day 4 in morphine treatment group. (q = 4.28,
P< 0.05). No significant difference was found in saline
treatment group (F(3, 21) = 0.32, P =0.81).
The repeated two-way ANOVA revealed that the
locomotor activity was dependent on the drug treat-
ment (F(1, 42) = 13.67, P< 0.01), days (F(3, 42) = 0.64,
P =0.59) and the interaction between the drug treatment
and the days (F(3, 42) = 1.96, P =0.13). Bonferroni post
hoc tests indicated that repeated morphine treatment
significantly increase locomotor activity of rat compared
to the corresponding saline control group on day 2
(t = 2.69, P< 0.05), day 3 (t = 2.98, P< 0.05) and day 4
(t = 4.07, P< 0.01).
Effects of baclofen on locomotor activity in rat
As shown in Figure 3a, one-way ANOVA revealed that
acute treatment with baclofen (1.25, 2.5, 5 mg/kg, s.c.)
had no significant effect on locomotor activity in rat
(F(3, 28) = 0.118, P> 0.05) (Figure 3a). After 8 continu-
ous days of treatment with saline or baclofen (1.25, 2.5,
5 mg/kg, s.c.), On day 8, the rats were administered sa-
line or baclofen and then put into the test chambers to
monitor the locomotor activity for 3 h. As shown inData are expressed as the means ± S.E.M. (n = 8 per group).
Figure 2 The induction of behavioral sensitization of morphine
in rat. Two groups of rats were exposed to morphine or saline for 4
consecutive days. Rats were given morphine or saline once daily on
day 1 and twice daily on days 2–4 as described previously. The
locomotor activity was monitored for 3 h in the chambers after the
first injection once daily. Each point represents the total distance
traveled for the 3 h test period. Data are shown as means ± S.E.M
(n = 8 per group). * P< 0.01 compared to the first administration
within group; # P< 0.05 and ## P< 0.01 compared to the
corresponding saline control group.Figure 3b, one-way ANOVA revealed that the loco-
motor activity of the baclofen-treated groups showed
no significant difference compared to the saline group
(F(3, 28) = 0.323, P> 0.05) (Figure 3b). High dose of baclo-
fen (5 mg/kg) decreased the locomotion activity, but
Newman-Keuls multiple comparison test indicated that
there is no significant difference compared to the saline
group(q = 2.35, P> 0.05).
Effects of baclofen on the acute morphine stimulation of
locomotion in rat
In order to study the effect of baclofen on acute morphine-
induced locomotion, rats pretreated with saline or baclofen
(1.25, 2.5, 5 mg/kg) and then challenged with morphine
on day 1. As shown in Figure 4a, morphine treatment on
day 1significantly enhanced locomotor activity in rats
compared to the saline control group (t = 3.98, P< 0.01).
One-way ANOVA revealed that baclofen pretreatment
inhibited the enhancement of acute morphine stimula-
tion of locomotion (F(4, 35) = 2.95, P< 0.05) (Fig. b).
Newman-Keuls multiple comparison test indicated that
Figure 4 Effects of single administration of baclofen on the
acute morphine stimulation of locomotor activity. Four groups
of rats were exposed to morphine and one group of rats was given
saline. For morphine treatment group, saline or baclofen (1.25, 2.5,
5 mg/kg, s.c.) was administered 15 min prior to the morphine
injection (b). Locomotor activity was measured for 3 h on day 1
immediately after morphine administration. Each bar represents the
total distance traveled for the 3 h test period. a: the saline/saline
group and morphine/saline group. Data are shown as means ± S.E.M
(n = 8 per group). ## P< 0.01 compared to saline/saline group; *
P< 0.05 compared to morphine/saline group.
Figure 5 Effects of acute treatment of baclofen on the expression
of morphine-induced sensitization. Four groups of rats were
exposed to morphine and one group of rats was given saline for 4
consecutive days as described previously. After a 3-day withdrawal
period, all five groups of animals were subjected to an acute challenge
of morphine (3 mg/kg, s.c.) on day 8. Four morphine-treated groups
were pretreated with saline or baclofen (1.25, 2.5, 5 mg/kg, s.c.) 15 min
prior to the morphine challenge (b). The locomotor activity was
monitored for 3 h in the chambers. Each bar represents the total
distance traveled for the 3 h test period. a: the saline/morphine group
and morphine/saline group. Data are shown as means ± S.E.M (n=7–8
per group). ## P< 0.01 compared to saline/morphine group; * P< 0.05
compared to morphine/saline group.
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of sensitization compared to the morphine/saline group
(q = 4.2, P< 0.05). There was no significant difference
in the locomotor activity between saline/morphine and
baclofen (1.25, 2.5 mg/kg)/morphine groups.
Effects of acute treatment of baclofen on the expression
of morphine-induced sensitization
After 4 days of repeated morphine treatment and 3 days
of withdrawal, all rats were challenged with morphine
(3 mg/kg) on day 8. As shown in Figure 5a, morphine
challenge induced significantly the expression of be-
havioral sensitization (t = 4.68, P< 0.01) in the repeated
morphine treatment group compared to saline control
group. One-way ANOVA showed that acute baclofen
pretreatment 15 min before morphine challenge dose-dependently inhibited the expression of morphine-induced
behavioral sensitization [F(4,35)=6.32, P< 0.01] (Figure 5b).
Newman-Keuls multiple comparison test indicated that
baclofen (5 mg/kg) significantly inhibited the expression
of morphine-induced behavioral sensitization (q = 3.31,
P< 0.05), while baclofen (1.25, 2.5 mg/kg) did not affect
significantly the magnitude of sensitization (P> 0.05).
Effects of chronic treatment of baclofen on the
development of morphine sensitization
As shown in Figure 6a, morphine challenge induced
significantly the expression of behavioral sensitization
(t = 5.07, P< 0.01) in the repeated morphine treatment
group compared to saline control group. One-way ANOVA
showed that chronic baclofen treatment dose-dependently
inhibited the development of morphine-induced
Figure 6 Effects of chronic treatment of baclofen on the
development of morphine sensitization. Four groups of rats were
exposed to morphine and one group of rats was given saline for 4
consecutive days. For morphine group, saline or baclofen (1.25, 2.5,
5 mg/kg, s.c.) was concomitantly administered 15 min prior to the
morphine injection. During a 3-day withdrawal period, rats in
morphine group were still injected with saline or baclofen (1.25, 2.5,
5 mg/kg, s.c.) daily (b). On day 8, all five groups of animals were
subjected to an acute challenge of morphine (3 mg/kg, s.c.). The
locomotor activity was monitored for 3 h in the chambers. Each bar
represents the total distance traveled for the 3 h test period. a: the
saline/morphine group and morphine/saline group. Data are shown
as means ± S.E.M (n = 8 per group). ## P< 0.01 compared to saline/
morphine group; * P< 0.05 and ** P< 0.01 compared to morphine/
saline group.
Figure 7 Effects of acute treatment of baclofen on morphine
challenge-induced release of dopamine in the NAc in rat. Drug
treatments are as described previously. After 4-day repeated
morphine administration, implantation of the microdialysis probes
was performed on day 5. On day 8, after basal levels of DA and
became stable (a), all rats were subjected to an acute challenge of
morphine (3 mg/kg, s.c.) . The dialysates were monitored for 3 h. DA
release was expressed as average increase of% basal level over 3 h
(b) and percentages of basal mean levels per 20-min intervals (c). ##
P< 0.01, compared to saline/morphine control group; * P< 0.05
compared to the morphine/saline treatment group; n = 8 per group.
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(Figure 6b). Newman-Keuls multiple comparison test
indicated that chronic baclofen (2.5, 5 mg/kg) signifi-
cantly inhibited the development of morphine-induced
behavioral sensitization (q = 2.85, P< 0.05; q = 3.59,
P< 0.01), while baclofen (1.25 mg/kg) did not affect sig-
nificantly the magnitude of sensitization (P> 0.05).
Effects of acute treatment of baclofen on morphine
challenge-induced release of dopamine in the NAc of rats
As shown in Figure 6a, acute baclofen treatment did not
effect the extracellular DA level in NAc before the final
morphine challenge [F(3,28) = 0.105, P = 0.349]. Figure 7b
indicated that morphine challenge significantly enhancedextracellular DA release in NAc in repeated morphine
administration compared to the saline control group
(t = 3.52, P< 0.01). Moreover, One-way ANOVA showed
that acute baclofen treatment significantly attenuated an
increase of extracellular DA release in NAc induced by
morphine challenge [F(3,28) = 3.12, P< 0.05]. The effects
of acute baclofen treatment on DA release in 20 min
interval were shown in Figure 7c, the repeated two-way
ANOVA revealed that the extracellular DA release in NAc
was dependent on the drug treatment (F(3, 252) = 9.36,
P< 0.05), times (F(9, 252) = 12.29, P< 0.01) and the
interaction between the drug treatment and the times
(F(27, 252) = 8.66, P< 0.05). Bonferroni post hoc tests
Fu et al. Behavioral and Brain Functions 2012, 8:20 Page 7 of 10
http://www.behavioralandbrainfunctions.com/content/8/1/20indicated that acute baclofen (5 mg/kg) treatment signifi-
cantly decrease DA release compared to the corresponding
saline control group on 60 min (t =2.84, P< 0.05), 100 min
(t = 3.15, P< 0.05) and 120 min (t = 2.91, P< 0.05). More-
over, baclofen (2.5 mg/kg) pretreatment attenuated extra-
cellular DA release in NAc and yet had no significant
effect.Figure 8 Effects of chronic treatment of baclofen on morphine
challenge-induced release of dopamine in the NAc in rat. Drug
treatments are as described previously. After 4-day repeated
morphine administration, implantation of the microdialysis probes
was performed during the 3-day morphine withdrawal period. On
day 8, after basal levels of DA and became stable (a), all rats were
subjected to an acute challenge of morphine (3 mg/kg, s.c.).The
dialysates were monitored for 3 h. DA release was expressed as
average increase of% basal level over 3 h (b) and percentages of
basal mean levels per 20-min intervals (c). ## P< 0.01, compared to
saline/morphine control group; * P< 0.05 and ** P< 0.01, compared
to the morphine/saline treatment group; n = 7–8 rats per group.Effects of chronic treatment of baclofen on release of
dopamine in the NAc of rats
As shown in Figure 8a , repeated morphine administration
did not change the extracellular DA level in NAc before the
final morphine challenge compared to saline control group
(t = 0.62, P =0.53). One-way ANOVA showed that chronic
baclofen treatment did not effect the extracellular DA
level in NAc before the final morphine challenge
[F(3,27) = 0.26, P = 0.42]. Figure 8b indicated that mor-
phine challenge significantly enhanced extracellular DA
release in NAc in repeated morphine administration
compared to the saline control group (t = 3.06, P< 0.01).
Moreover, One-way ANOVA showed that chronic baclo-
fen treatment significantly attenuated an increase of
extracellular DA release in NAc induced by morphine
challenge [F(3,27) = 4.95, P< 0.01]. Newman-Keuls mul-
tiple comparison test indicated that chronic baclofen
(2.5, 5 mg/kg) significantly suppressed extracellular DA re-
lease in NAc after morphine challenge (q= 2.96, P< 0.05;
q = 4.51, P< 0.01). The effects of chronic baclofen treat-
ment on DA release in 20 min interval were shown in
Figure 8c, the repeated two-way ANOVA revealed that
the extracellular DA release in NAc was dependent on
the drug treatment (F(3, 251) = 12.17, P< 0.01), times
(F(9, 251) = 15.31, P< 0.01) and the interaction between
the drug treatment and the times (F(27, 251) = 10.62, P
< 0.01). Bonferroni post hoc tests indicated that acute
baclofen (5 mg/kg) treatment significantly decrease DA
release compared to the corresponding saline control
group on 60 min (t = 3.26, P< 0.05), 80 min (t = 2.97,
P< 0.05) , 100 min (t = 3.67, P< 0.05), 120 min (t = 2.98,
P< 0.05) and 140 min (t = 3.91, P< 0.05). Moreover,
baclofen (2.5 mg/kg) pretreatment attenuated extracel-
lular DA release in NAc on 80 min (t = 2.79, P< 0.05)
and 120 min (t = 3.05, P< 0.05).Discussion
In recent years, GABAB receptor agonist has received a con-
siderable research interest for its extensive therapeutic
implications associated with alcohol dependence [28], co-
caine abuse [20,29], nicotine [30,31] and opiates addiction
[32-34]. An involvement of GABAB receptor agonist in
modulating dopaminergic effects related to opiates abuse
have been reported by several previous studies [18,34,35],
which is encouraging to consider the possibility that GABABreceptor agonist could play an important role in opiates
addiction.
Baclofen, a potent GABAB receptor agonist was deter-
mined to attenuate morphine discriminative stimulus
effects [32], inhibit morphine withdrawal signs [36,37] and
decreased morphine-induced hyperactivity in mice [38].
However, its potential role in morphine sensitization in
rats still remains to investigate further. From this perspec-
tive, in the present work, we determined to evaluate that
the effect of baclofen on the development and expression
of morphine-induced behavioral sensitization. In addition,
extracellular DA release in NAc was also detected.
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in rats had been reported [39]. However, in our study, we
systemically evaluated the effect of baclofen on development
and expression of morphine sensitization and dopamine
release in NA in rats. The main finding of the present work
is that repeated baclofen administration during 4-day con-
secutive morphine administration and 3-day withdrawal
period inhibits the acquisition and expression of morphine
sensitization and dopamine release in the shell of NAc,
which are consistent with previous reports that the shell of
NAc plays a critical role in the behavioral sensitization
[27,40].
Repeated administration of opiates can lead to increased
locomotor activity which is called behavioral sensitization
[41-44]. It has been widely recognized that behavioral
sensitization plays an important role in drug addiction such
as relapse [45,46], compulsive drug-seeking [47-49]. Based
on the crucial role of behavioral sensitization in drug addic-
tion, it is necessary to investigate the effect of baclofen on
morphine-induced behavioral sensitization which can also
provide new insights into the understanding of potential
mechanism underlying the morphine dependence. The
present study confirmed that repeated morphine adminis-
tration for 4 days in rat produces an increase in locomotion
activity in response to an acute challenge of morphine fol-
lowing 3 days of withdrawal period, which was in agreement
with preliminary studies [26,50], suggesting the development
of locomotion sensitization. Furthermore, our current find-
ings showed that chronic treatment with different doses of
baclofen significantly inhibited the development of behav-
ioral sensitization induced by morphine. In addition, acute
treatment of only high dose of baclofen has effect on mor-
phine sensitization. The present study provides the evidence
that the increased GABA release is really suppressed mor-
phine-induced sensitization which suggested the possibility
that GABA transmission plays a key role in sensitization.
There are substantial findings revealed that mesolimbic
DAergic pathway might be involved in modulating behav-
ioral sensitization [51], especially the nucleus accumbens
which receives DAergic projection arising from DA neu-
rons in the ventral tegmental area (VTA) [11,13,14,52]. To
detect the possible mechanism contribute to the inhibition
of baclofen on behavioral sensitization following repeated
exposure to morphine, we assessed the effect of baclofen
on extracellular DA release in NAc. Results showed that,
after 3 days withdrawal following repeated morphine ad-
ministration, morphine challenge significantly increased
extracellular DA release in NAc, consistent with the previ-
ous report [50]. It is also found that pretreatment with
baclofen significantly prevents enhancement of extracellu-
lar DA release in NAc induced by morphine challenge.
The NAc includes a medioventral shell region and a
dorsolateral core region and receive dopaminergic and
GABAergic projections from the VTA and other regions[53]. Previous studies had shown that GABAB receptor
activation in the VTA reduced the synaptic dopamine
release in the NAc [7,53]. Therefore, Activation of GABAB
receptors localized on dopaminergic neurons in the VTA
might be involved in the effect of baclofen in our study
which attenuated both the development and expression of
morphine sensitization and dopamine release in the shell
of NAc. Moreover, GABAB receptors have been found in
the NAc and other region. The effect of baclofen on acqui-
sition and expression of morphine sensitization might be
also induced by GABAB receptor activation in the shell of
NAc.
Conclusions
Our results have demonstrated that acute morphine
challenge induced behavioral sensitization after repeated
morphine administration followed by 3 days withdrawal
period. The fact that the GABAB receptor agonist, baclo-
fen, dose-dependently inhibited morphine sensitization
by prevention of extracellular DA release in NAc has fur-
ther confirmed that GABAergic neurotransmission could
be participated in modulating morphine sensitization.
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